Ovid Therapeutics, Inc. (OVID) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Phibro Animal Health Corp.

Soleno Therapeutics, Inc.

Arcutis Biotherapeutics, Inc.

Ovid Therapeutics, Inc.

MacroGenics, Inc.

EyePoint Pharmaceuticals, Inc.

Erasca, Inc.

Oric Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc.

Fulcrum Therapeutics, Inc.

Third Harmonic Bio, Inc.

Why is Ovid Therapeutics, Inc. ?

Poor long term growth as Operating profit has grown by an annual rate 8.01% of over the last 5 years

Flat results in Sep 25

PRE-TAX PROFIT(Q) At USD -12.16 MM has Fallen at -45.99%
NET PROFIT(Q) At USD -12.16 MM has Fallen at -45.99%
ROCE(HY) Lowest at -60.06%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 444.68%, its profits have risen by 12.9%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Ovid Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Ovid Therapeutics, Inc.

440.18%

-0.19

115.98%

S&P 500

13.68%

0.71

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-0.88%

EBIT Growth (5y)

8.01%

EBIT to Interest (avg)

-27.73

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.70

Sales to Capital Employed (avg)

0.03

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

76.22%

ROCE (avg)

ROE (avg)

12.05%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.68

EV to EBIT

-5.62

EV to EBITDA

-5.68

EV to Capital Employed

11.20

EV to Sales

34.75

PEG Ratio

Dividend Yield

ROCE (Latest)

-199.32%

ROE (Latest)

-70.39%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company

NET SALES(HY)

At USD 6.4 MM has Grown at 1,772.51%

OPERATING CASH FLOW(Y)

Highest at USD -37.93 MM

NET PROFIT(HY)

Higher at USD -16.84 MM

RAW MATERIAL COST(Y)

Fallen by -6,474.05% (YoY

-16What is not working for the Company

PRE-TAX PROFIT(Q)

At USD -12.16 MM has Fallen at -45.99%

NET PROFIT(Q)

At USD -12.16 MM has Fallen at -45.99%

ROCE(HY)

Lowest at -60.06%

CASH AND EQV(HY)

Lowest at USD 63.95 MM

DEBT-EQUITY RATIO (HY)

Highest at -26.49 %

Here's what is working for Ovid Therapeutics, Inc.

Net Sales

At USD 6.4 MM has Grown at 1,772.51%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Operating Cash Flow

Highest at USD -37.93 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Raw Material Cost

Fallen by -6,474.05% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Ovid Therapeutics, Inc.

Pre-Tax Profit

At USD -12.16 MM has Fallen at -45.99%

over average net sales of the previous four periods of USD -8.33 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -12.16 MM has Fallen at -45.99%

over average net sales of the previous four periods of USD -8.33 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Cash and Eqv

Lowest at USD 63.95 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -26.49 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio